AYTU BioPharma, Inc. (AYTU) Q3 2024 Earnings

AYTU·Reported November 13, 2024·After market close

AYTU BioPharma, Inc. reported Q3 2024 revenue of $16.6M, beat analyst consensus of $13.8M by $2.8M. Diluted EPS came in at $-0.20, beat the $-0.34 consensus by $0.14.

Revenue

$16.6Mbeat by $2.8M

Consensus: $13.8M

Diluted EPS

$-0.20beat by $0.14

Consensus: $-0.34

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0001437749-24-034970

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q3 2024 Earnings FAQ

Common questions about AYTU BioPharma, Inc.'s Q3 2024 earnings report.

AYTU BioPharma, Inc. (AYTU) reported Q3 2024 earnings on November 13, 2024 after market close.

AYTU BioPharma, Inc. reported revenue of $16.6M and diluted EPS of $-0.20 for Q3 2024.

Revenue beat the consensus estimate of $13.8M by $2.8M. EPS beat the consensus estimate of $-0.34 by $0.14.

You can read the 10-Q periodic report (0001437749-24-034970) directly on SEC EDGAR. The filing index links above go to sec.gov.